Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $32.37, demonstrating a +2.65% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.58%. Prior to today's trading, shares of the company had gained 24.79% outpaced the Medical sector's gain of 2.74% and the S&P 500's gain of 3.68%.Investors will be eagerly watching for the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$0.71 per share. This would mark a year-over-year decline of 222.73%. For the annual period, the Zacks Consensus Estimates anticipate earnings of -$2.48 per share and a revenue of $0 million, signifying shifts of -145.54% and 0%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Viking Therapeutics, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #4 (Sell). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks